A Highlight of recent advances in aptamer technology and its application

Molecules

Volumn 20, Issue 7, 2015, Pages 11959-11980

  Sun, Hongguang ^a   Zu, Youli ^a  

^a HOUSTON METHODIST HOSPITAL   (United States)

Author keywords

Application; Aptamer; Improvement; Modification; Optimization; SELEX

Indexed keywords

APTAMER;

HUMAN; SYSTEMATIC EVOLUTION OF LIGANDS BY EXPONENTIAL ENRICHMENT APTAMER TECHNIQUE;

APTAMERS, NUCLEOTIDE; HUMANS; SELEX APTAMER TECHNIQUE;

EID: 84938498309     PISSN: None     EISSN: 14203049     Source Type: Journal    
DOI: 10.3390/molecules200711959     Document Type: Review

References (133)

1. Ellington, A.D.; Szostak, J.W. In vitro selection of RNA molecules that bind specific ligands. Nature 1990, 346, 818-822.
2. Tuerk, C.; Gold, L. Systematic evolution of ligands by exponential enrichment: RNA ligands to bacteriophage T4 DNA polymerase. Science 1990, 249, 505-510.
3. Saberian-Borujeni, M.; Johari-Ahar, M.; Hamzeiy, H.; Barar, J.; Omidi, Y. Nanoscaled aptasensors for multi-analyte sensing. BioImpacts:BI 2014, 4, 205-215.
4. Hermann, T.; Patel, D.J. Adaptive recognition by nucleic acid aptamers. Science 2000, 287, 820-825.
5. Nimjee, S.M.; Rusconi, C.P.; Sullenger, B.A. Aptamers: An emerging class of therapeutics. Annu. Rev. Med. 2005, 56, 555-583.
6. McNamara, J.O.; Kolonias, D.; Pastor, F.; Mittler, R.S.; Chen, L.; Giangrande, P.H.; Sullenger, B.; Gilboa, E. Multivalent 4-1BB binding aptamers costimulate CD8+ T cells and inhibit tumor growth in mice. J. Clin. Investig. 2008, 118, 376-386.
7. Zhou, B.; Wang, B. Pegaptanib for the treatment of age-related macular degeneration. Exp. Eye Res. 2006, 83, 615-619.
8. Eyetech Study Group. Preclinical and phase 1A clinical evaluation of an anti-VEGF pegylated aptamer (EYE001) for the treatment of exudative age-related macular degeneration. Retina 2002, 22, 143-152.
9. Ireson, C.R.; Kelland, L.R. Discovery and development of anticancer aptamers. Mol. Cancer Ther. 2006, 5, 2957-2962.
10. Lao, Y.H.; Phua, K.K.; Leong, K.W. Aptamer nanomedicine for cancer therapeutics: Barriers and potential for translation. ACS Nano 2015, 9, 2235-2254.
11. Xiang, D.; Shigdar, S.; Qiao, G.; Wang, T.; Kouzani, A.Z.; Zhou, S.F.; Kong, L.; Li, Y.; Pu, C.; Duan, W. Nucleic acid aptamer-guided cancer therapeutics and diagnostics: The next generation of cancer medicine. Theranostics 2015, 5, 23-42.
12. Ciesiolka, J.; Gorski, J.; Yarus, M. Selection of an RNA domain that binds Zn2+. RNA 1995, 1, 538-550.
13. Yang, Q.; Goldstein, I.J.; Mei, H.Y.; Engelke, D.R. DNA ligands that bind tightly and selectively to cellobiose. Proc. Natl. Acad. Sci. USA 1998, 95, 5462-5467.
14. Stoltenburg, R.; Nikolaus, N.; Strehlitz, B. Capture-SELEX: Selection of DNA Aptamers for Aminoglycoside Antibiotics. J. Anal. Methods Chem. 2012, 2012, 415697.
15. Liu, Z.; Duan, J.H.; Song, Y.M.; Ma, J.; Wang, F.D.; Lu, X.; Yang, X.D. Novel HER2 aptamer selectively delivers cytotoxic drug to HER2-positive breast cancer cells in vitro. J. Transl. Med. 2012, 10, 148, doi:10.1186/1479-5876-10-148.
16. Shangguan, D.; Li, Y.; Tang, Z.; Cao, Z.C.; Chen, H.W.; Mallikaratchy, P.; Sefah, K.; Yang, C.J.; Tan, W. Aptamers evolved from live cells as effective molecular probes for cancer study. Proc. Natl. Acad. Sci. USA 2006, 103, 11838-11843.
17. Li, S.; Xu, H.; Ding, H.; Huang, Y.; Cao, X.; Yang, G.; Li, J.; Xie, Z.; Meng, Y.; Li, X.; et al. Identification of an aptamer targeting hnRNP A1 by tissue slide-based SELEX. J. Pathol. 2009, 218, 327-336.
18. Darmostuk, M.; Rimpelova, S.; Gbelcova, H.; Ruml, T. Current approaches in SELEX: An update to aptamer selection technology. Biotechnol. Adv. 2015, doi:10.1016/j.biotechadv.2015.02.008.
19. Lin, H.; Zhang, W.; Jia, S.; Guan, Z.; Yang, C.J.; Zhu, Z. Microfluidic approaches to rapid and efficient aptamer selection. Biomicrofluidics 2014, 8, 041501, doi:10.1063/1.4890542.
20. Gold, L.; Ayers, D.; Bertino, J.; Bock, C.; Bock, A.; Brody, E.N.; Carter, J.; Dalby, A.B.; Eaton, B.E.; Fitzwater, T.; et al. Aptamer-based multiplexed proteomic technology for biomarker discovery. PLoS ONE 2010, 5, e15004.
21. Elle, I.C.; Karlsen, K.K.; Terp, M.G.; Larsen, N.; Nielsen, R.; Derbyshire, N.; Mandrup, S.; Ditzel, H.J.; Wengel, J. Selection of LNA-containing DNA aptamers against recombinant human CD73. Mol. Biosyst. 2015, 11, 1260-1270.
22. Daniels, D.A.; Chen, H.; Hicke, B.J.; Swiderek, K.M.; Gold, L. A tenascin-C aptamer identified by tumor cell SELEX: systematic evolution of ligands by exponential enrichment. Proc. Natl. Acad. Sci. USA 2003, 100, 15416-15421.
23. Sefah, K.; Shangguan, D.; Xiong, X.; O'Donoghue, M.B.; Tan, W. Development of DNA aptamers using Cell-SELEX. Nat. Protoc. 2010, 5, 1169-1185.
24. Cibiel, A.; Dupont, D.M.; Duconge, F. Methods To Identify Aptamers against Cell Surface Biomarkers. Pharmaceuticals 2011, 4, 1216-1235.
25. Cerchia, L.; de Franciscis, V. Targeting cancer cells with nucleic acid aptamers. Trends Biotechnol. 2010, 28, 517-525.
26. Bruno, J.G. Predicting the Uncertain Future of Aptamer-Based Diagnostics and Therapeutics. Molecules 2015, 20, 6866-6887.
27. Ng, E.W.; Adamis, A.P. Anti-VEGF aptamer (pegaptanib) therapy for ocular vascular diseases. Ann. N.Y. Acad. Sci. 2006, 1082, 151-171.
28. Sun, H.; Zhu, X.; Lu, P.Y.; Rosato, R.R.; Tan, W.; Zu, Y. Oligonucleotide aptamers: New tools for targeted cancer therapy. Mol. Ther. Nucleic Acids 2014, 3, e182.
29. Osborne, S.E.; Matsumura, I.; Ellington, A.D. Aptamers as therapeutic and diagnostic reagents: Problems and prospects. Curr. Opin. Chem. Biol. 1997, 1, 5-9.
30. Stovall, G.M.; Bedenbaugh, R.S.; Singh, S.; Meyer, A.J.; Hatala, P.J.; Ellington, A.D.; Hall, B. In vitro selection using modified or unnatural nucleotides. Curr. Protoc. Nucleic Acid Chem. 2014, 56, doi:10.1002/0471142700.nc0906s56.
31. Burmeister, P.E.; Lewis, S.D.; Silva, R.F.; Preiss, J.R.; Horwitz, L.R.; Pendergrast, P.S.; McCauley, T.G.; Kurz, J.C.; Epstein, D.M.; Wilson, C.; et al. Direct in vitro selection of a 2′-O-methyl aptamer to VEGF. Chem. Biol. 2005, 12, 25-33.
32. Proske, D.; Gilch, S.; Wopfner, F.; Schatzl, H.M.; Winnacker, E.L.; Famulok, M. Prion-protein-specific aptamer reduces PrPSc formation. Chembiochem 2002, 3, 717-725.
33. Ruckman, J.; Green, L.S.; Beeson, J.; Waugh, S.; Gillette, W.L.; Henninger, D.D.; Janjic, N.; Claesson-Welsh, L. 2′-Fluoropyrimidine RNA-based aptamers to the 165-amino acid form of vascular endothelial growth factor (VEGF165). Inhibition of receptor binding and VEGF-induced vascular permeability through interactions requiring the exon 7-encoded domain. J. Biol. Chem. 1998, 273, 20556-20567.
34. Keefe, A.D.; Cload, S.T. SELEX with modified nucleotides. Curr. Opin. Chem. Biol. 2008, 12, 448-456.
35. Wu, S.Y.; Yang, X.; Gharpure, K.M.; Hatakeyama, H.; Egli, M.; McGuire, M.H.; Nagaraja, A.S.; Miyake, T.M.; Rupaimoole, R.; Pecot, C.V.; et al. 2′-OMe-phosphorodithioate-modified siRNAs show increased loading into the RISC complex and enhanced anti-tumour activity. Nat. Commun. 2014, 5, 3459, doi:10.1038/ncomms4459.
36. Yu, D.; Wang, D.; Zhu, F.G.; Bhagat, L.; Dai, M.; Kandimalla, E.R.; Agrawal, S. Modifications incorporated in CpG motifs of oligodeoxynucleotides lead to antagonist activity of toll-like receptors 7 and 9. J. Med. Chem. 2009, 52, 5108-5114.
37. Forster, C.; Zydek, M.; Rothkegel, M.; Wu, Z.; Gallin, C.; Gessner, R.; Lisdat, F.; Furste, J.P. Properties of an LNA-modified ricin RNA aptamer. Biochem. Biophys. Res. Commun. 2012, 419, 60-65.
38. Pinheiro, V.B.; Taylor, A.I.; Cozens, C.; Abramov, M.; Renders, M.; Zhang, S.; Chaput, J.C.; Wengel, J.; Peak-Chew, S.Y.; McLaughlin, S.H.; et al. Synthetic genetic polymers capable of heredity and evolution. Science 2012, 336, 341-344.
39. Eulberg, D.; Klussmann, S. Spiegelmers: Biostable aptamers. Chembiochem 2003, 4, 979-983.
40. Parekh, P.; Kamble, S.; Zhao, N.; Zeng, Z.; Portier, B.P.; Zu, Y. Immunotherapy of CD30-expressing lymphoma using a highly stable ssDNA aptamer. Biomaterials 2013, 34, 8909-8917.
41. King, D.J.; Ventura, D.A.; Brasier, A.R.; Gorenstein, D.G. Novel combinatorial selection of phosphorothioate oligonucleotide aptamers. Biochemistry 1998, 37, 16489-16493.
42. Eaton, B.E. The joys of in vitro selection: Chemically dressing oligonucleotides to satiate protein targets. Curr. Opin. Chem. Biol. 1997, 1, 10-16.
43. Davies, D.R.; Gelinas, A.D.; Zhang, C.; Rohloff, J.C.; Carter, J.D.; O'Connell, D.; Waugh, S.M.; Wolk, S.K.; Mayfield, W.S.; Burgin, A.B.; et al. Unique motifs and hydrophobic interactions shape the binding of modified DNA ligands to protein targets. Proc. Natl. Acad. Sci. USA 2012, 109, 19971-19976.
44. Kraemer, S.; Vaught, J.D.; Bock, C.; Gold, L.; Katilius, E.; Keeney, T.R.; Kim, N.; Saccomano, N.A.; Wilcox, S.K.; Zichi, D.; et al. From SOMAmer-based biomarker discovery to diagnostic and clinical applications: A SOMAmer-based, streamlined multiplex proteomic assay. PLoS ONE 2011, 6, e26332.
45. Kimoto, M.; Yamashige, R.; Matsunaga, K.; Yokoyama, S.; Hirao, I. Generation of high-affinity DNA aptamers using an expanded genetic alphabet. Nat. Biotechnol. 2013, 31, 453-457.
46. Keefe, A.D.; Pai, S.; Ellington, A. Aptamers as therapeutics. Nat. Rev. Drug Discov. 2010, 9, 537-550.
47. Tan, L.; Neoh, K.G.; Kang, E.T.; Choe, W.S.; Su, X. PEGylated anti-MUC1 aptamer-doxorubicin complex for targeted drug delivery to MCF7 breast cancer cells. Macromol. Biosci. 2011, 11, 1331-1335.
48. Taghdisi, S.M.; Danesh, N.M.; Sarreshtehdar Emrani, A.; Tabrizian, K.; Zandkarimi, M.; Ramezani, M.; Abnous, K. Targeted delivery of Epirubicin to cancer cells by PEGylated A10 aptamer. J. Drug Target. 2013, 21, 739-744.
49. Macugen, A.M.D.S.G.; Apte, R.S.; Modi, M.; Masonson, H.; Patel, M.; Whitfield, L.; Adamis, A.P. Pegaptanib 1-year systemic safety results from a safety-pharmacokinetic trial in patients with neovascular age-related macular degeneration. Ophthalmology 2007, 114, 1702-1712.
50. Basile, A.S.; Hutmacher, M.; Nickens, D.; Nielsen, J.; Kowalski, K.; Whitfield, L.; Masayo, O.; Nakane, M. Population pharmacokinetics of pegaptanib in patients with neovascular, age-related macular degeneration. J. Clin. Pharmacol. 2012, 52, 1186-1199.
51. Shiang, Y.C.; Ou, C.M.; Chen, S.J.; Ou, T.Y.; Lin, H.J.; Huang, C.C.; Chang, H.T. Highly efficient inhibition of human immunodeficiency virus type 1 reverse transcriptase by aptamers functionalized gold nanoparticles. Nanoscale 2013, 5, 2756-2764.
52. Wu, Y.; Sefah, K.; Liu, H.; Wang, R.; Tan, W. DNA aptamer-micelle as an efficient detection/delivery vehicle toward cancer cells. Proc. Natl. Acad. Sci. USA 2010, 107, 5-10.
53. Hall, B.; Micheletti, J.M.; Satya, P.; Ogle, K.; Pollard, J.; Ellington, A.D. Design, synthesis, and amplification of DNA pools for in vitro selection. Curr. Protoc. Mol. Biol. 2009, doi:10.1002/0471142700.nc0902s00.
54. Kulbachinskiy, A.V. Methods for selection of aptamers to protein targets. Biochem. Biokhimiia 2007, 72, 1505-1518.
55. Bruno, J.G. A review of therapeutic aptamer conjugates with emphasis on new approaches. Pharmaceuticals 2013, 6, 340-357.
56. Mallikaratchy, P.R.; Ruggiero, A.; Gardner, J.R.; Kuryavyi, V.; Maguire, W.F.; Heaney, M.L.; McDevitt, M.R.; Patel, D.J.; Scheinberg, D.A. A multivalent DNA aptamer specific for the B-cell receptor on human lymphoma and leukemia. Nucleic Acids Res. 2011, 39, 2458-2469.
57. VEGF Inhibition Study in Ocular Neovascularization (V.I.S.I.O.N.) Clinical Trial Group; Chakravarthy, U.; Adamis, A.P.; Cunningham, E.T., Jr.; Goldbaum, M.; Guyer, D.R.; Katz, B.; Patel, M. Year 2 efficacy results of 2 randomized controlled clinical trials of pegaptanib for neovascular age-related macular degeneration. Ophthalmology 2006, 113, 1508 e1-e25.
58. Ibach, J.; Dietrich, L.; Koopmans, K.R.; Nobel, N.; Skoupi, M.; Brakmann, S. Identification of a T7 RNA polymerase variant that permits the enzymatic synthesis of fully 2′-O-methyl-modified RNA. J. Biotechnol. 2013, 167, 287-295.
59. Santosh, B.; Yadava, P.K. Nucleic acid aptamers: Research tools in disease diagnostics and therapeutics. BioMed. Res. Int. 2014, 2014, 540451, doi:10.1155/2014/540451.
60. Duclair, S.; Gautam, A.; Ellington, A.; Prasad, V.R. High-affinity RNA Aptamers Against the HIV-1 Protease Inhibit Both in Vitro Protease Activity and Late Events of Viral Replication. Mol. Ther. Nucleic Acids 2015, 4, e228.
61. Lennarz, S.; Alich, T.C.; Kelly, T.; Blind, M.; Beck, H.; Mayer, G. Selective aptamer-based control of intraneuronal signaling. Angew. Chem. 2015, 54, 5369-5373.
62. Luo, Z.; Zhou, H.; Jiang, H.; Ou, H.; Li, X.; Zhang, L. Development of a fraction collection approach in capillary electrophoresis SELEX for aptamer selection. Analyst 2015, 140, 2664-2670.
63. Berezovski, M.; Drabovich, A.; Krylova, S.M.; Musheev, M.; Okhonin, V.; Petrov, A.; Krylov, S.N. Nonequilibrium capillary electrophoresis of equilibrium mixtures: A universal tool for development of aptamers. J. Am. Chem. Soc. 2005, 127, 3165-3171.
64. Tolle, F.; Wilke, J.; Wengel, J.; Mayer, G. By-product formation in repetitive PCR amplification of DNA libraries during SELEX. PLoS ONE 2014, 9, e114693.
65. Yufa, R.; Krylova, S.M.; Bruce, C.; Bagg, E.A.; Schofield, C.J.; Krylov, S.N. Emulsion PCR significantly improves nonequilibrium capillary electrophoresis of equilibrium mixtures-based aptamer selection: allowing for efficient and rapid selection of aptamer to unmodified ABH2 protein. Anal. Chem. 2015, 87, 1411-1419.
66. Ouellet, E.; Foley, J.H.; Conway, E.M.; Haynes, C. Hi-Fi SELEX: A high-fidelity digital-PCR based therapeutic aptamer discovery platform. Biotechnol. Bioeng. 2015, doi:10.1002/bit.25581.
67. Hunniger, T.; Wessels, H.; Fischer, C.; Paschke-Kratzin, A.; Fischer, M. Just in time-selection: A rapid semiautomated SELEX of DNA aptamers using magnetic separation and BEAMing. Anal. Chem. 2014, 86, 10940-10947.
68. Zhang, Y.; Xu, H.; Zhou, H.; Wu, F.; Su, Y.; Liang, Y.; Zhou, D. Indirect purification method provides high yield and quality ssDNA sublibrary for potential aptamer selection. Anal. Biochem. 2015, 476, 84-90.
69. Guo, W.M.; Kong, K.W.; Brown, C.J.; Quah, S.T.; Yeo, H.L.; Hoon, S.; Seow, Y. Identification and Characterization of an eIF4e DNA Aptamer That Inhibits Proliferation With High Throughput Sequencing. Mol. Ther. Nucleic Acids 2014, 3, e217.
70. Eaton, R.M.; Shallcross, J.A.; Mael, L.E.; Mears, K.S.; Minkoff, L.; Scoville, D.J.; Whelan, R.J. Selection of DNA aptamers for ovarian cancer biomarker HE4 using CE-SELEX and high-throughput sequencing. Anal. Bioanal. Chem. 2015, doi:10.1007/s00216-015-8665-7.
71. Zhou, J.; Satheesan, S.; Li, H.; Weinberg, M.S.; Morris, K.V.; Burnett, J.C.; Rossi, J.J. Cell-specific RNA aptamer against human CCR5 specifically targets HIV-1 susceptible cells and inhibits HIV-1 infectivity. Chem. Biol. 2015, 22, 379-390.
72. Hoinka, J.; Berezhnoy, A.; Sauna, Z.E.; Gilboa, E.; Przytycka, T.M. AptaCluster - A Method to Cluster HT-SELEX Aptamer Pools and Lessons from its Application. In Research in Computational Molecular Biology, Proceedings of the Annual International Conference, RECOMB, Pittsburgh, PA, USA, 2-5 April 2014; Volume 8394, pp. 115-128.
73. Hoinka, J.; Berezhnoy, A.; Dao, P.; Sauna, Z.E.; Gilboa, E.; Przytycka, T.M. Large scale analysis of the mutational landscape in HT-SELEX improves aptamer discovery. Nucleic Acids Res. 2015, doi:10.1093/nar/gkv308.
74. AptaTools. Available online: http://www.ncbi.nlm.nih.gov/CBBresearch/Przytycka/index.cgi#aptatools (accessed on 06 Jun 2015).
75. Ahmad Raston, N.H.; Gu, M.B. Highly amplified detection of visceral adipose tissue-derived serpin (vaspin) using a cognate aptamer duo. Biosens. Bioelectron. 2015, 70, 261-267.
76. Cho, M.; Oh, S.S.; Nie, J.; Stewart, R.; Radeke, M.J.; Eisenstein, M.; Coffey, P.J.; Thomson, J.A.; Soh, H.T. Array-based discovery of aptamer pairs. Anal. Chem. 2015, 87, 821-828.
77. Lao, Y.H.; Chiang, H.Y.; Yang, D.K.; Peck, K.; Chen, L.C., Selection of aptamers targeting the sialic acid receptor of hemagglutinin by epitope-specific SELEX. Chem. Commun. 2014, 50, 8719-8722.
78. Cho, M.; Soo Oh, S.; Nie, J.; Stewart, R.; Eisenstein, M.; Chambers, J.; Marth, J.D.; Walker, F.; Thomson, J.A.; Soh, H.T. Quantitative selection and parallel characterization of aptamers. Proc. Natl. Acad. Sci. USA 2013, 110, 18460-18465.
79. Qiao, L.; Lv, B.; Feng, X.; Li, C. A new application of aptamer: One-step purification and immobilization of enzyme from cell lysates for biocatalysis. J. Biotechnol. 2015, 203, 68-76.
80. Yang, Z.; Kasprzyk-Hordern, B.; Goggins, S.; Frost, C.G.; Estrela, P. A novel immobilization strategy for electrochemical detection of cancer biomarkers: DNA-directed immobilization of aptamer sensors for sensitive detection of prostate specific antigens. Analyst 2015, 140, 2628-2633.
81. Alsager, O.A.; Kumar, S.; Zhu, B.; Travas-Sejdic, J.; McNatty, K.P.; Hodgkiss, J.M. Ultrasensitive colorimetric detection of 17beta-estradiol: The effect of shortening DNA aptamer sequences. Anal. Chem. 2015, 87, 4201-4209.
82. Cai, S.; Li, G.; Zhang, X.; Xia, Y.; Chen, M.; Wu, D.; Chen, Q.; Zhang, J.; Chen, J. A signal-on fluorescent aptasensor based on single-stranded DNA-sensitized luminescence of terbium (III) for label-free detection of breast cancer cells. Talanta 2015, 138, 225-230.
83. Viraka Nellore, B.P.; Kanchanapally, R.; Pramanik, A.; Sinha, S.S.; Chavva, S.R.; Hamme, A., 2nd; Ray, P.C. Aptamer-conjugated graphene oxide membranes for highly efficient capture and accurate identification of multiple types of circulating tumor cells. Bioconjug. Chem. 2015, 26, 235-242.
84. Ho, L.C.; Wu, W.C.; Chang, C.Y.; Hsieh, H.H.; Lee, C.H.; Chang, H.T. Aptamer-Conjugated Polymeric Nanoparticles for the Detection of Cancer Cells through "Turn-On" Retro-Self-Quenched Fluorescence. Anal. Chem. 2015, 87, 4925-4932.
85. Zheng, F.; Cheng, Y.; Wang, J.; Lu, J.; Zhang, B.; Zhao, Y.; Gu, Z. Aptamer-functionalized barcode particles for the capture and detection of multiple types of circulating tumor cells. Adv. Mater. 2014, 26, 7333-7338.
86. Jo, H.; Her, J.; Ban, C. Dual aptamer-functionalized silica nanoparticles for the highly sensitive detection of breast cancer. Biosens. Bioelectron. 2015, 71, 129-136.
87. Zhang, P.; Zhao, N.; Zeng, Z.; Feng, Y.; Tung, C.H.; Chang, C.C.; Zu, Y. Using an RNA aptamer probe for flow cytometry detection of CD30-expressing lymphoma cells. Lab. Investig. 2009, 89, 1423-1432.
88. Zeng, Z.; Zhang, P.; Zhao, N.; Sheehan, A.M.; Tung, C.H.; Chang, C.C.; Zu, Y. Using oligonucleotide aptamer probes for immunostaining of formalin-fixed and paraffin-embedded tissues. Mod. Pathol. 2010, 23, 1553-1558.
89. Pu, Y.; Liu, Z.; Lu, Y.; Yuan, P.; Liu, J.; Yu, B.; Wang, G.; Yang, C.J.; Liu, H.; Tan, W. Using DNA aptamer probe for immunostaining of cancer frozen tissues. Anal. Chem. 2015, 87, 1919-1924.
90. Li, H.; Hu, H.; Zhao, Y.; Chen, X.; Li, W.; Qiang, W.; Xu, D. Multifunctional aptamer-silver conjugates as theragnostic agents for specific cancer cell therapy and fluorescence-enhanced cell imaging. Anal. Chem. 2015, 87, 3736-3745.
91. Jacobson, O.; Yan, X.; Niu, G.; Weiss, I.D.; Ma, Y.; Szajek, L.P.; Shen, B.; Kiesewetter, D.O.; Chen, X. PET Imaging of Tenascin-C with a Radiolabeled Single-Stranded DNA Aptamer. J. Nucl. Med. 2015, 56, 616-621.
92. Zeng, Z.; Parekh, P.; Li, Z.; Shi, Z.Z.; Tung, C.H.; Zu, Y. Specific and sensitive tumor imaging using biostable oligonucleotide aptamer probes. Theranostics 2014, 4, 945-952.
93. Lee, J.; Kang, H.J.; Jang, H.; Lee, Y.J.; Lee, Y.S.; Ali, B.A.; Al-Khedhairy, A.A.; Kim, S. Simultaneous imaging of two different cancer biomarkers using aptamer-conjugated quantum dots. Sensors 2015, 15, 8595-8604.
94. Melancon, M.P.; Zhou, M.; Zhang, R.; Xiong, C.; Allen, P.; Wen, X.; Huang, Q.; Wallace, M.; Myers, J.N.; Stafford, R.J.; et al. Selective uptake and imaging of aptamer- and antibody-conjugated hollow nanospheres targeted to epidermal growth factor receptors overexpressed in head and neck cancer. ACS Nano 2014, 8, 4530-4538.
95. Qiu, L.; Chen, T.; Ocsoy, I.; Yasun, E.; Wu, C.; Zhu, G.; You, M.; Han, D.; Jiang, J.; Yu, R.; et al. A cell-targeted, size-photocontrollable, nuclear-uptake nanodrug delivery system for drug-resistant cancer therapy. Nano Lett. 2015, 15, 457-463.
96. Liao, Z.X.; Chuang, E.Y.; Lin, C.C.; Ho, Y.C.; Lin, K.J.; Cheng, P.Y.; Chen, K.J.; Wei, H.J.; Sung, H.W. An AS1411 aptamer-conjugated liposomal system containing a bubble-generating agent for tumor-specific chemotherapy that overcomes multidrug resistance. J. Controll. Release 2015, 208, 42-51.
97. Liang, C.; Guo, B.; Wu, H.; Shao, N.; Li, D.; Liu, J.; Dang, L.; Wang, C.; Li, H.; Li, S.; et al. Aptamer-functionalized lipid nanoparticles targeting osteoblasts as a novel RNA interference-based bone anabolic strategy. Nat. Med. 2015, 21, 288-294.
98. Zhao, N.; Bagaria, H.G.; Wong, M.S.; Zu, Y. A nanocomplex that is both tumor cell-selective and cancer gene-specific for anaplastic large cell lymphoma. J. Nanobiotechnol. 2011, 9, 2, doi:10.1186/1477-3155-9-2.
99. Yang, L.; Zhang, Y.; Li, R.; Lin, C.; Guo, L.; Qiu, B.; Lin, Z.; Chen, G. Electrochemiluminescence biosensor for ultrasensitive determination of ochratoxin A in corn samples based on aptamer and hyperbranched rolling circle amplification. Biosens. Bioelectron. 2015, 70, 268-274.
100. Wei, X.; Tian, T.; Jia, S.; Zhu, Z.; Ma, Y.; Sun, J.; Lin, Z.; Yang, C.J. Target-responsive DNA hydrogel mediated "stop-flow" microfluidic paper-based analytic device for rapid, portable and visual detection of multiple targets. Anal. Chem. 2015, 87, 4275-4282.
101. Wu, W.; Zhao, S.; Mao, Y.; Fang, Z.; Lu, X.; Zeng, L. A sensitive lateral flow biosensor for Escherichia coli O157:H7 detection based on aptamer mediated strand displacement amplification. Anal. Chim. Acta 2015, 861, 62-68.
102. Ye, B.F.; Zhao, Y.J.; Cheng, Y.; Li, T.T.; Xie, Z.Y.; Zhao, X.W.; Gu, Z.Z. Colorimetric photonic hydrogel aptasensor for the screening of heavy metal ions. Nanoscale 2012, 4, 5998-6003.
103. Wu, X.; Chen, J.; Wu, M.; Zhao, J.X. Aptamers: Active targeting ligands for cancer diagnosis and therapy. Theranostics 2015, 5, 322-344.
104. Xiang, D.; Shigdar, S.; Qiao, G.; Zhou, S.F.; Li, Y.; Wei, M.Q.; Qiao, L.; Shamaileh, H.A.; Zhu, Y.; Zheng, C.; et al. Aptamer-mediated cancer gene therapy. Curr. Gene Ther. 2015, 15, 109-119.
105. Sun, H.; Zu, Y. Aptamers and Their Applications in Nanomedicine. Small 2015, doi:10.1002/smll.201403073.
106. Zhou, J.; Rossi, J.J. Cell-type-specific, Aptamer-functionalized Agents for Targeted Disease Therapy. Mol. Ther. Nucleic Acids 2014, 3, e169.
107. Chen, A.; Yang, S. Replacing antibodies with aptamers in lateral flow immunoassay. Biosens. Bioelectron. 2015, 71, 230-242.
108. Wu, J.; Zhu, Y.; Xue, F.; Mei, Z.; Yao, L.; Wang, X.; Zheng, L.; Liu, J.; Liu, G.; Peng, C.; et al. Recent trends in SELEX technique and its application to food safety monitoring. Mikrochim. Acta 2014, 181, 479-491.
109. Hayat, A.; Marty, J.L. Aptamer based electrochemical sensors for emerging environmental pollutants. Front. Chem. 2014, 2, 41, doi:10.3389/fchem.2014.00041.
110. Shangguan, D.; Cao, Z.; Meng, L.; Mallikaratchy, P.; Sefah, K.; Wang, H.; Li, Y.; Tan, W. Cell-specific aptamer probes for membrane protein elucidation in cancer cells. J. Proteome Res. 2008, 7, 2133-2139.
111. Tang, Z.; Shangguan, D.; Wang, K.; Shi, H.; Sefah, K.; Mallikratchy, P.; Chen, H.W.; Li, Y.; Tan, W. Selection of aptamers for molecular recognition and characterization of cancer cells. Anal. Chem. 2007, 79, 4900-4907.
112. Mallikaratchy, P.; Tang, Z.; Kwame, S.; Meng, L.; Shangguan, D.; Tan, W. Aptamer directly evolved from live cells recognizes membrane bound immunoglobin heavy mu chain in Burkitt's lymphoma cells. Mol. Cell. Proteomics MCP 2007, 6, 2230-2238.
113. Hou, Z.; Meyer, S.; Propson, N.E.; Nie, J.; Jiang, P.; Stewart, R.; Thomson, J.A. Characterization and target identification of a DNA aptamer that labels pluripotent stem cells. Cell Res. 2015, 25, 390-393.
114. Kaur, J.; Tikoo, K. Ets1 identified as a novel molecular target of RNA aptamer selected against metastatic cells for targeted delivery of nano-formulation. Oncogene 2015, doi:10.1038/onc.2014.447.
115. Ayoglu, B.; Chaouch, A.; Lochmuller, H.; Politano, L.; Bertini, E.; Spitali, P.; Hiller, M.; Niks, E.H.; Gualandi, F.; Ponten, F.; et al. Affinity proteomics within rare diseases: A BIO-NMD study for blood biomarkers of muscular dystrophies. EMBO Mol. Med. 2014, 6, 918-936.
116. Roux-Dalvai, F.; Gonzalez de Peredo, A.; Simo, C.; Guerrier, L.; Bouyssie, D.; Zanella, A.; Citterio, A.; Burlet-Schiltz, O.; Boschetti, E.; Righetti, P.G.; et al. Extensive analysis of the cytoplasmic proteome of human erythrocytes using the peptide ligand library technology and advanced mass spectrometry. Mol. Cell. Proteomics MCP 2008, 7, 2254-2269.
117. Hathout, Y.; Brody, E.; Clemens, P.R.; Cripe, L.; DeLisle, R.K.; Furlong, P.; Gordish-Dressman, H.; Hache, L.; Henricson, E.; Hoffman, E.P.; et al. Large-scale serum protein biomarker discovery in Duchenne muscular dystrophy. Proc. Natl. Acad. Sci. USA 2015, 112, 7153-7158.
118. Kobayashi, H.; Choyke, P.L. Target-cancer-cell-specific activatable fluorescence imaging probes: Rational design and in vivo applications. Acc. Chem. Res. 2011, 44, 83-90.
119. Zeng, Z.; Tung, C.H.; Zu, Y. A cancer cell-activatable aptamer-reporter system for one-step assay of circulating tumor cells. Mol. Ther. Nucleic Acids 2014, 3, e184.
120. Georges, J.F.; Liu, X.; Eschbacher, J.; Nichols, J.; Mooney, M.A.; Joy, A.; Spetzler, R.F.; Feuerstein, B.G.; Preul, M.C.; Anderson, T.; et al. Use of a conformational switching aptamer for rapid and specific ex vivo identification of central nervous system lymphoma in a xenograft model. PLoS ONE 2015, 10, e0123607.
121. Zhu, Z.; Tang, Z.; Phillips, J.A.; Yang, R.; Wang, H.; Tan, W. Regulation of singlet oxygen generation using single-walled carbon nanotubes. J. Am. Chem. Soc. 2008, 130, 10856-10857.
122. Rusconi, C.P.; Scardino, E.; Layzer, J.; Pitoc, G.A.; Ortel, T.L.; Monroe, D.; Sullenger, B.A. RNA aptamers as reversible antagonists of coagulation factor IXa. Nature 2002, 419, 90-94.
123. Cohen, M.G.; Purdy, D.A.; Rossi, J.S.; Grinfeld, L.R.; Myles, S.K.; Aberle, L.H.; Greenbaum, A.B.; Fry, E.; Chan, M.Y.; Tonkens, R.M.; et al. First clinical application of an actively reversible direct factor IXa inhibitor as an anticoagulation strategy in patients undergoing percutaneous coronary intervention. Circulation 2010, 122, 614-622.
124. Subramanian, N.; Raghunathan, V.; Kanwar, J.R.; Kanwar, R.K.; Elchuri, S.V.; Khetan, V.; Krishnakumar, S. Target-specific delivery of doxorubicin to retinoblastoma using epithelial cell adhesion molecule aptamer. Mol. Vis. 2012, 18, 2783-2795.
125. Hu, Y.; Duan, J.; Zhan, Q.; Wang, F.; Lu, X.; Yang, X.D. Novel MUC1 aptamer selectively delivers cytotoxic agent to cancer cells in vitro. PLoS ONE 2012, 7, e31970.
126. Bagalkot, V.; Farokhzad, O.C.; Langer, R.; Jon, S. An aptamer-doxorubicin physical conjugate as a novel targeted drug-delivery platform. Angew. Chem. 2006, 45, 8149-8152.
127. Subramanian, N.; Kanwar, J.R.; Akilandeswari, B.; Kanwar, R.K.; Khetan, V.; Krishnakumar, S. Chimeric nucleolin aptamer with survivin DNAzyme for cancer cell targeted delivery. Chem. Commun. 2015, 51, 6940-6943.
128. McNamara, J.O., 2nd; Andrechek, E.R.; Wang, Y.; Viles, K.D.; Rempel, R.E.; Gilboa, E.; Sullenger, B.A.; Giangrande, P.H. Cell type-specific delivery of siRNAs with aptamer-siRNA chimeras. Nat. Biotechnol. 2006, 24, 1005-1015.
129. Thiel, K.W.; Hernandez, L.I.; Dassie, J.P.; Thiel, W.H.; Liu, X.; Stockdale, K.R.; Rothman, A.M.; Hernandez, F.J.; McNamara, J.O., 2nd; Giangrande, P.H. Delivery of chemo-sensitizing siRNAs to HER2+-breast cancer cells using RNA aptamers. Nucleic Acids Res. 2012, 40, 6319-6337.
130. Dai, F.; Zhang, Y.; Zhu, X.; Shan, N.; Chen, Y. The anti-chemoresistant effect and mechanism of MUC1 aptamer-miR-29b chimera in ovarian cancer. Gynecol. Oncol. 2013, 131, 451-459.
131. Esposito, C.L.; Cerchia, L.; Catuogno, S.; de Vita, G.; Dassie, J.P.; Santamaria, G.; Swiderski, P.; Condorelli, G.; Giangrande, P.H.; de Franciscis, V. Multifunctional aptamer-miRNA conjugates for targeted cancer therapy. Mol. Ther. 2014, 22, 1151-1163.
132. Ni, X.; Zhang, Y.; Ribas, J.; Chowdhury, W.H.; Castanares, M.; Zhang, Z.; Laiho, M.; DeWeese, T.L.; Lupold, S.E. Prostate-targeted radiosensitization via aptamer-shRNA chimeras in human tumor xenografts. J. Clin. Investig. 2011, 121, 2383-2390.
133. Nucleic Acid Aptamers for Diagnostics and Therapeutics: Global Markets. Available online: http://www.marketresearch.com/BCC-Research-v374/Nucleic-Acid-Aptamers-Diagnostics-Therapeutics-8412378/ (accessed on 25 May 2015).